AstraZeneca shares plunge 15 percent as lung cancer study fails
Reuters: Health News
LONDON (Reuters) - AstraZeneca's combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday.
No comments:
Post a Comment